G1 Therapeutics, Inc.
g1therapeutics.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2024 10-Q, filed Aug 8, 2024. Its latest SEC filing is a SC 13G/A from Nov 13, 2024.
10-Q for Q2 FY2024, filed Aug 8, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Sells COSELA, a cancer drug used before chemotherapy to protect patients' bone marrow, and develops other cancer treatments.
10-K for FY2023, filed Feb 28, 2024We are a commercial-stage biopharmaceutical company focused on the development and commercialization of novel small molecule therapeutics…View ↗
On February 12, 2021, FDA approved COSELA (trilaciclib for intravenous injection) to decrease the incidence of chemotherapy-induced…View ↗
Beyond our continued development and commercialization of our initial ES-SCLC indication in the U.S., we are focusing our efforts on two…View ↗
How Did They Make Money?
U.S. specialty distributors buy COSELA, and the sale is counted when the product reaches their facilities. License revenue comes from upfront and milestone payments for rights, plus royalties tied to licensees' sales.
10-K for FY2023, filed Feb 28, 2024The Company sells COSELA to specialty distributors in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time…View ↗
Licenses of Intellectual PropertyView ↗
At the inception of each arrangement that includes developmental and regulatory milestone payments, the Company evaluates whether the…View ↗
RoyaltiesView ↗
-
10-K for FY2023, filed Feb 28, 2024
FY2023 revenue by product or service ↗
$82.5M
-
10-K for FY2023, filed Feb 29, 2024
$82.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product sales, net
Sold outright
10-K for FY2023, filed Feb 28, 2024 |
56%
FY2020: 0.0%
|
Product sales, net, FY2023
$46.3M Sources
|
Sold outright |
|
License revenue
Licensed
10-K for FY2023, filed Feb 28, 2024 |
44%
FY2020: 100%
|
License revenue, FY2023
$36.2M Sources
|
Licensed |
Who Were Their Customers?
Specialty distributors buy COSELA in the United States; pharmaceutical partners receive licenses to develop and commercialize drug candidates in specified markets.
10-K for FY2023, filed Feb 28, 2024The Company sells COSELA to specialty distributors in the U.S. and, in accordance with ASC 606, recognizes revenue at the point in time…View ↗
On August 3, 2020, the Company entered into an exclusive license agreement with Simcere for the development and commercialization of…View ↗
On June 15, 2020, the Company entered into an exclusive license agreement with Genor Biopharma Co. Inc. (“Genor”) for the development and…View ↗
Did Revenues Turn Into Profits?
No. It lost $48M in FY2023.
10-K for FY2023, filed Feb 29, 2024
−$39.5MView ↗
10-K for FY2023, filed Feb 29, 2024
−$48MView ↗
10-K for FY2023, filed Feb 29, 2024
−$38.3MView ↗
How Were They Changing?
- Net income
-
Sources
10-Q for Q2 FY2024, filed Aug 9, 2024
−$5.5MView ↗
- ▼ Now a loss
- vs $8.7M in Q2 FY2023
10-Q for Q2 FY2024, filed Aug 8, 2024
Open tableView ↗
-
Sep 18, 2024
Pharmacosmos completed its acquisition of G1
G1 became a wholly owned subsidiary, and its shares ceased trading on Nasdaq.
Sources
8-K, filed Sep 18, 2024
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender OfferView ↗
-
Aug 8, 2024
Reaffirmed COSELA sales forecast
The 2024 forecast remained between $60 million and $70 million.
Sources
8-K, filed Aug 8, 2024
1 G1 Therapeutics Provides Second Quarter 2024 Financial Results and Operational Highlights - Entered into Definitive Merger Agreement to…View ↗
Loading...
